Management of Embolic Events During Pregnancy

Introduction to Embolic Events

The European Society of Cardiology recommends low-molecular-weight heparin (LMWH) as the treatment of choice for pulmonary embolism in pregnancy, administered as therapeutic fixed doses based on early pregnancy weight throughout the entire pregnancy, with thrombolysis or surgical embolectomy reserved exclusively for life-threatening, high-risk PE with hemodynamic instability 1, 2, 3

Pulmonary embolism is the most common embolic complication requiring anticoagulation therapy 1
Amniotic fluid embolism is a rare but catastrophic condition occurring during pregnancy or shortly after delivery, with a case fatality rate of 13-19% and an incidence of approximately 27 per 100,000 maternities 1, 4

Formal diagnostic assessment with validated methods is mandatory if PE is suspected during pregnancy or postpartum, with a Class I recommendation 1, 4
D-dimer measurement and clinical prediction rules should be considered to rule out PE, with a Class IIa recommendation 1, 4
The diagnostic algorithm should start with a chest radiograph as the first radiation-associated procedure in all cases 2, 5

LMWH is the anticoagulant of choice, administered as therapeutic fixed doses based on early pregnancy weight, and should be continued throughout the entire pregnancy 2, 3
NOACs, including apixaban, are explicitly contraindicated during pregnancy and lactation 3
Unfractionated heparin (UFH) may be considered as an alternative, particularly when rapid reversal is needed 3
Anticoagulation should be continued for at least 6 weeks postpartum, with a minimum overall treatment duration of 3 months 1, 2, 3

Thrombolysis or surgical embolectomy should be considered for pregnant women with high-risk PE 1, 2, 4
Thrombolytic treatment should not be used peri-partum except in life-threatening PE settings 1, 2, 4

LMWH should be discontinued at the onset of regular uterine contractions, and UFH infusion should be stopped 4-6 hours prior to anticipated delivery 2, 3
Regional anesthesia should not be performed within 24 hours of therapeutic LMWH dose, and activated partial thromboplastin time should be normal prior to regional anesthesia 1, 2, 3, 4

Management of amniotic fluid embolism is entirely supportive, with aggressive life support, and high-quality cardiopulmonary resuscitation as the initial immediate response 1, 4

A multidisciplinary pregnancy heart team should collaborate in planning ante-, peri-, and postpartum care pathways, with expertise in PE management during pregnancy and postpartum period 1, 2, 4

NOACs should never be used during pregnancy, and thrombolysis should be avoided peri-partum unless truly life-threatening PE with hemodynamic collapse 1, 2, 3, 4
Regional anesthesia should not be performed within 24 hours of therapeutic LMWH dose, and overdiagnosis of PE should be avoided due to lifelong implications 1, 2, 3, 4, 5